Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I trial of TO-206 in Japanese cedar pollinosis
jRCT2080222215Phase 1
- Sponsor
- Torii Pharmaceutical
- Start
- Sep 2013
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing TO-206 sublingual with Placebo sublingual (2 arms). Primary endpoint: Primary safety endpoints.
02
Drugs
japanese cedar pollen
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on jRCT2080222215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222215.